Doximity has reported revenue of approximately $ 344M for FY2022

DoxymetryA networking platform for healthcare professionals posted revenue of $ 93.7 million for the fourth quarter ended March 31, compared to $ 66.7 million in the same quarter last year.

The company had a net worth of $ 36.7 million, compared to 21.5 million last year. Doximity also released its FY 2022 results, which brought in $ 343.5 million compared to 20 206.9 million in 2021, ending March 31, 2021. It reported full-year net income of $ 154.8 million, compared to 50.2 million.

For the next quarter, which ends June 30, Doximity posted revenue guidelines ranging from $ 88.6 million to $ 89.6 million. For the full year, which ends March 31, 2023, it forecasts revenues ranging from $ 454 million to $ 458 million.

During an earnings call, Doximity co-founder and CEO Jeff Tanny said the company had more than two million registered members in the quarter and recorded record high usage for its fax, e-signature and telehealth products. It announced and finalized the acquisition of its doctor-scheduling and messaging app Amion during Q4.

“Adding to our workflow suite, we have successfully Has stopped our acquisition of Amion.com, which powers a schedule of 200,000 US physicians. Combined with our telehealth tools used by over 350,000 unique physicians, NPs and PAs over the last quarter, we believe we will become the Physician Cloud in the United States, a kind of Bloomberg for physicians, “he said.


Prescription Digital Therapeutic Company Pear Therapeutics reported earnings of প্রথম 2.7 million in its first quarter, compared to $ 376,000 in the first quarter of 2021 and $ 1.3 million in Q4.

This is a post Net loss of $ 23.86 million compared to 24.39 million in the first quarter of last year. Pear reported more than 9,200 prescriptions for its products in Q1 and predicted that it would report 50,000 to 60,000 prescriptions for the full year.

“Our momentum continued in 2021 with strong revenue and prescription growth in the first quarter until 2022,” President and CEO Dr. Corey McCann said in a statement.

“We continue to expand the reach of our products with progress from CMS recognition through HCPCS codes, setting the milestone of reset and reset-O in Spanish, expansion to new states like Oklahoma and Michigan and a significant reward for PDT. We also have clinical results.” We are moving forward with our provider’s pricing offer, including 12-month and 24-month health economic data, showing long-term declines in sustainability and access to healthcare resources. “

Leave a Reply

Your email address will not be published.